Tier 4 — mechanistic

Dietary Quercetin and Kaempferol: Bioavailability and Potential Cardiovascular-Related Bioactivity in Humans

Wijdan M Dabeek, Melissa Ventura Marra
Nutrients 2019 11(10):2288

Bibliography

PubMed
PMID 31557798
PubMed Central
PMC6835347
DOI
10.3390/nu11102288
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignNarrative review of human dietary bioavailability and vascular evidence
ModelNarrative or mixed evidence review
SampleFood and supplementation studies; no new clinical cohort
InterventionQuercetin and kaempferol glycosides, aglycones, and metabolites
DurationLiterature available at publication
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2019, this source examined cardiovascular and metabolic health. Its evidence base was Food and supplementation studies; no new clinical cohort. It evaluated Quercetin and kaempferol glycosides, aglycones, and metabolites across Literature available at publication.

Chemical form and food matrix affect absorption, and selected trials suggest vascular biomarker effects.

The review cannot establish a universal effective dose or infer clinical benefit from the most concentrated food source or highest plasma exposure.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Chemical form and food matrix affect absorption, and selected trials suggest vascular biomarker effects.
  • The recorded outcome domains were Exposure and pharmacokinetics.

What this study can and cannot tell us

  • The review cannot establish a universal effective dose or infer clinical benefit from the most concentrated food source or highest plasma exposure.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 4
Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms
Abigail J Larson et al. · Advances in nutrition (Bethesda, Md.) · 2012

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology